[A case of hemolytic uremic syndrome after adjuvant chemotherapy with gemcitabine in a patient with pancreatic cancer].
Nihon Shokakibyo Gakkai Zasshi
; 107(10): 1676-85, 2010 Oct.
Article
en Ja
| MEDLINE
| ID: mdl-20938119
ABSTRACT
A 63-year-old man with Stage IVa pancreas tail cancer was admitted for a distal pancreatectomy and splenectomy; adjuvant chemotherapy with gemcitabine was also administered. The chemotherapy was terminated after 16 courses due to hemolytic anemia, thrombocytopenia and renal dysfunction. Plasma exchange was performed; however the patient's renal function was diminished, requiring chronic hemodialysis. Physicians should be cautious of hemolytic uremic syndrome as a possible adverse reaction to gemcitabine and be aware that tests are needed for its early detection.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Neoplasias Pancreáticas
/
Desoxicitidina
/
Síndrome Hemolítico-Urémico
/
Antimetabolitos Antineoplásicos
Tipo de estudio:
Screening_studies
Límite:
Humans
/
Male
/
Middle aged
Idioma:
Ja
Revista:
Nihon Shokakibyo Gakkai Zasshi
Año:
2010
Tipo del documento:
Article